Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $112
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $102 to $112.
Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $102 to $112.